



SCS
Swiss Chemical
Society

Community News

www.scg.ch

www.chemanager-online.com

SWISS CHEMICAL SOCIETY NEWS

Inauguration Event of the SCS Flow Chemistry Network at ILMAC Basel 2021



In the framework of the ILMAC 2021 Forum, organized by the Swiss Chemical Society, the 1st Swiss Flow Chemistry Symposium took place in Basel on October 19, 2021. The symposium was the inauguration event for the SCS Flow Chemistry Network that provides a platform for academic and industrial scientists to develop and support initiatives in

the field of continuous flow chemistry reactions and to showcase the potential of this promising approach for more sustainable industrial processes.

Dr. Claudio Battilocchio from Syngenta Crop Protection, as the chair of the network, welcomed more than 100 interested participants on-site and online. Seven invited lecturers and a roundtable discussion filled the program with interesting talks that showcased some of the great opportunities associated with this enabling technology.

With this symposium, that might be organized on an annual basis, the network aims to bring together the great potential of flow chemistry and the entire vibrant community around it. 48 SCS members are currently connected to the Flow Chemistry Network. If you like to be involved into the network and be actively informed about their activities please login to your account on the SCS website and click the flow chemistry checkbox.

More information: scg.ch/flow-chemistry

ILMAC 2021 Forum, Basel – Almost Back to Normality



Despite the challenges of the Corona pandemic, the organizers of ILMAC Basel 2021 can look back on a successful fair. From October 19 to 21, almost 7,000 professionals and exhibitors came to Messe Basel to learn about and discuss innovative products, systems and applications for the entire laboratory value chain in industry and academic

research. ILMAC Basel was the only industry meeting place in the German-speaking countries so far this year.

For three days, 250 leading suppliers from the life sciences sector presented to the visitors, who came predominantly from Switzerland, the latest developments and topics relating to laboratory technology, analytics and biotechnology. ILMAC's new digital platform also offers the community a meeting place after the event to exchange information, share ideas and publicize events and new products. The platform presented at ILMAC was extremely well received and has around 6,000 members. From now on, ILMAC exhibitors will not only reach trade visitors at the live event, but 365 days a year.

SCS Symposia in the ILMAC Forum

On October 19 at 10.00h Alain De Mesmaeker, president of the SCS, opened the forum with the Swiss Flow Chemistry Symposium as a pivotal event of the Swiss Flow Chemistry Network activities. Seven lectures and a roundtable discussions provided the latest findings in the field.

The 2nd symposium in the forum was dedicated to the 2nd Green & Sustainable Chemistry Day with 8 lectures of invited experts from all over Europe and the award lecture of the Green & Sustainable Chemistry Award 2021. As part of the program also the four finalists of the Swiss CleanTech Award 2021, sponsored by Clariant, presented their project in a 10 min short talk each. The first prize was given to Selina Kaiser, ETH Zurich, for her outstanding project on «Nanostructured Catalysts for Sustainable Acetylene-Based Vinyl Chloride Production». Michael Carus, Co-Founder of the Renewable Carbon Initiative, Nova-Institut, Germany rounded off the evening with an exciting and stimulating presentation on «Renewable Carbon Concept and Initiative for a Sustainable Chemical Industry of the Future».

The focus of the last symposium on Artificial Intelligence & Digitalization in Chemical Research was on the exploitation of synthesis data, as well as on the advances in the analysis and design of new materials and active ingredients. Hans Peter Luethi, Swiss Chemical Society as well as Torsten Luksch and Arndt Finkelmann, Syngenta Crop Protection, led through the day as chairmen.

More information: ilmac.ch

New Website of the SCS Foundation



The SCS Foundation implemented its new website that shows its supported initiatives in a structured and modern way and gives easy access to information about the organization.

The SCS Foundation promotes research and education in the natural sciences, in particular in the fields of chemistry and biochemistry and supports various Scholarship-, Award- and Mentoring-Programs. The programs of the SCS Foundation are financed by donations from companies and private donors.

Alfred Werner Scholarship Program

The program supports highly talented students to perform their Master of Science (MSc) studies in Chemistry, Biochemistry or the Pharmaceutical Sciences at a Swiss University or at one of the Swiss Federal Institutes of Technology. The program targets students from foreign countries ranking in the top ten percent of their bachelor (BSc) programs. As of this year, the scholarships amount to CHF 30,000.

Award Programs

The Swiss Chemistry Travel Award facilitates the participation of selected PhD students at international conferences in the chemical sciences. It's a joint initiative of SCNAT and the SCS.

The Best Presentation Awards at the SCS Fall Meeting

For each of the thematic parallel sessions. The best oral- and poster-presenters receive prizes with a total value of more than CHF 42'000 CHF.

Website: scs-foundation.ch

EuChemS Historical Landmarks Award 2020



The Justus Liebig's Laboratory has been awarded the EuChemS Historical Landmarks Award in recognition of the role it played in the history of chemistry and the European sense of belonging between people and ideas. Located in Gießen (State of Hesse) in Germany, the chemist Justus von Liebig worked in this laboratory from 1824 to 1852. He subsequently worked in Munich until his death in 1873.

Justus von Liebig is considered as one of the main founders of organic chemistry and is well known for his major contributions to agricultural and biological chemistry. Liebig is also recognised for transforming chemistry education: he is one of the first chemists who engaged with his students by combining research and teaching in a laboratory – as we know it in its present form. Furthermore, Liebig was a truly European figure: his major advisor – who also directed his PhD thesis – was Karl Wilhelm Gottlob Kastner, while he did what today would be called his postdoc with Guy-Lussac. He popularised chemistry through his book *Chemische Briefe* (1844) which was widely disseminated and translated in Europe, and founded the journal *Annalen der Chemie* (1832), later known as *Liebigs Annalen*, which became the leading journal in chemistry and is still in circulation today as the *European Journal of Organic Chemistry*.

Erected in 1818, Justus Liebig's Laboratory building was turned into a museum in 1920. Rich collections of historical documents, including hundreds of letters, chemistry books, pictures, chemical apparatus, scientific instruments, and personal memorabilia make the Liebig Museum one of the most impressive chemistry museums worldwide. It is also one of the oldest laboratory buildings remaining, where the visitor can experience the original function and the working conditions of the time when chemistry entered the universities. Moreover, technical installations, including ovens, hoods, and drainage, remain well preserved.

On the occasion of Liebig's 200th birthday in 2003, his place of work in Gießen was awarded the 'Historic sites of Chemistry' Award (*Historische Stätten der Chemie*) of the German Chemical Society (GDCh), a EuChemS Member Society.

Source: euchems.eu

GRAND PRIX 2022 de la Fondation de la Maison de la Chimie – Call for Nominations



The award is meant to honor an original work in chemistry of benefit to humankind, society or nature and was created in 1986 on the initiative of the board of the Fondation de la Maison de la Chimie. In 2022, The Grand Prix will be awarded for the eighteenth time to one or several persons, irrespective of nationality. It carries a monetary award of 35,000 Euros.

Entry forms, accompanied by a report in French or English detailing the arguments for the nomination, must be returned – by electronic mail – before 30th April 2022. Nominations will

be evaluated by a jury composed of renowned members of the international scientific community. Unsuccessful entries may be renewed for subsequent awards of the Prize. Nominations must be presented by a learned Society or a national or international scientific Organization.

The laureate will be invited to deliver a lecture on her/his work at an award ceremony that will take place at the Maison de la Chimie in February 2023.

More information: actions.maisondelachimie.com

Swiss Academies Reports: Photon Science Roadmap



On a mandate of the Confederation, the Swiss Academy of Sciences (SCNAT) develops individual roadmaps for scientific research infrastructures. Overall, there is a total of 8 roadmaps (astronomy, space science, high energy physics, biology, chemistry, geosciences, neutron science and photon science) published altogether in March 2021. The Photon

Science roadmap distills findings and recommendations with respect to large scale photon sources for the period 2025 to 2028. It includes three chapters, one on synchrotrons, one on XFELs and one on support infrastructure, such as 'Fastlabs'. Each chapter provides details to back-up the main recommendations.

More information: swissphotonscience.ch

A Warm Welcome to Our New Members!



Period: 28.09.–26.10.2021

Yimon Aye, Lausanne – Valeria Bertoz-Françoise Amina Aouane, Bülach – Joel Keller, Basel – Youngdon Ko, Sion – Miroslava Nedyalkova, Marly – David Rombach, Zurich – Manuel Stehrenberger, Wädenswil – Maria Inés Velasco, Geneva – Yan B. Vogel, Delft (NL).

HONORS, AWARDS, APPOINTMENTS

Prof. Michael Grätzel, EPFL Lausanne wins 2022 Rank Prize for Optoelectronics



Prof. Michael Grätzel at EPFL's School of Basic Sciences is one of the seven winners of this year's prize. Michael Grätzel, who became world-famous for the invention of dye-sensitized solar cells (popularly known as "Grätzel cells") directs the Laboratory of Photonics and Interfaces within the Institute of Chemical Sciences and Engineering (ISIC).


The Rank Prize was created in 1972 by Lord Arthur J. Rank (1888–1972), a prominent British film producer and philanthropist, to advance research in two fields of research Rank himself pursued during his own career: human and animal nutrition, and optoelectronics.

Since its foundation, the Rank Prize for Optoelectronics is given every two years. The 2022 Prize is awarded to seven internationally leading scientists, from several research laboratories

“for pioneering the development of new solar cell technology based on perovskite semiconductors which promises to play a key role in the future of solar power.”

Source: actu.epfl.ch

Prof. Eva Hevia, University of Bern: Recipient of the 2021 Arfvedson Schlenk Prize



Prof. Eva Hevia from the Department Chemistry, Biochemistry and Pharmaceutical Sciences of the University of Bern is the winner of the Arfvedson-Schlenk Prize 2021. Prof. Hevia received the award in recognition of her outstanding research work at the interface between inorganic, organic and green chemistry, which has set

important milestones in polar organometallic chemistry. She has shown in a remarkable way that important organolithium reactions can take place in air and moisture, whereby volatile organic solvents can be replaced by alternatives. Furthermore, she developed cooperative bimetallic methods for the selective functionalization of aromatics and heterocycles, which enabled the detection of unknown organometallic intermediates. Her work points the way to a practical and sustainable future of polar organometallic chemistry.

The Arfvedson Schlenk Prize is awarded to scientists for outstanding work in the field of lithium chemistry. In 1997 the Prize was set up by Chemetall, Frankfurt a.M. together with the GDCh. It was followed by the sponsor Rockwood Lithium, which became Albermarle Germany GmbH, which now sponsors the award.

Source: gdch.de

Winners of the Swiss CleanTech Award 2021



Clariant and the Swiss Chemical Society were partnering to award the Swiss CleanTech Award 2021 as part of the «2nd Green & Sustainable Chemistry Day» at the ILMAC Basel on October 20, 2021. The pre-selected four finalists were invited to give a 10min short talk and based on the application dossiers and the presentations, the jury decided

on the winners and the distribution of the prize money of total CHF 10,000 on site.

Dr. Martin Volmer, CTO of Clariant introduced the prize and handed over the trophies to the awardees.

Winner of the Swiss CleanTech Award 2021

Selina K. Kaiser, ETH Zurich

«Nanostructured Catalysts for Sustainable Acetylene-Based Vinyl Chloride Production»

Runner-up 2. place

Scott R. Docherty, ETH Zurich

«Bimetallic Palladium-Gallium Catalysts for the Hydrogenation of CO₂ to Methanol»

Runner-up 3. place

Wooseok Yang, University of Zurich

«Conversion of solar energy into a vector suitable for storage using Sb₂Se₃» and

Ahmed Elabd, University of Fribourg

«Functional Mechanically Interlocked Polymers for Stabilizing High Energy Density Batteries»

The program honors outstanding scientific achievements of Master students, PhD students, and Postdocs in Switzerland in the field of Sustainable Chemistry, in areas such as resource efficiency, renewable energy, renewable raw materials or green technologies and environmental protection. The finalists are invited to present their projects in a 10min short presentation

More information: scg.ch/cleantech-award

Dandelion Entrepreneurship Award for Prof. Jean-Christophe Leroux, ETH Zurich



Prof. Jean-Christophe Leroux, Institute of Pharmaceutical Sciences at ETH Zurich was honored online on September 10, 2021 with the Dandelion Entrepreneurship Award 2021 for building bridges between fundamental research and applied sciences. Three of his technologies have been licensed to pharmaceutical companies and he is the scientific advisor for the lab's

spin-offs *Inositec* and *Versantis.ting*.

The award recognizes professors for their outstanding efforts to promote entrepreneurship at ETH Zurich and was given for the first time this year by ETH Entrepreneur Club and ETH AI Center.

Source: chab.ethz.ch

Prof. Christer Kiselman gave the 2020 Chaim Weizmann Lecture at University of Fribourg




Each year, the Chemistry Department at University of Fribourg selects a top-level scholar for its prestigious Chaim Weizmann Lecture. On October 15, 2021, Professor Katharina Fromm welcomed **Prof. Christer Kiselman**, Mathematics Professor at University of Uppsala, Sweden and member of the Royal Swedish Society of

Sciences with his speech “A life with Mathematics and Languages”.

Chaim Weizmann, the first president of Israel, was also a renowned chemist, and received his PhD from University of Fribourg in 1899, before contributing to creating the Weizmann Institute near Tel-Aviv, Israel.

Source: unifr.ch.

Prof. Ali Coskun, University of Fribourg, awarded a SNSF Sinergia Grant



Prof. Ali Coskun and his research team have just been awarded a prestigious 4-year SNSF Sinergia grant for their groundbreaking project entitled “Pushing All Solid-State Batteries to Their Full Potential – Interface Engineering Guided by Advanced Diagnostics for High Performance Scalable Batteries.”

In the context of a real boom around the world in demand for renewable energy technologies and an increasing need to store this energy safely, for instance to power electric vehicles, this exciting new project proposes to develop research into all solid-state batteries. Prof. Coskun chose a par-

ticularly international and collaborative approach for this project, seeking partners whose expertise in different fields will enable him to solve important issues inherent to all solid-state batteries, notably relating to interface and engineering: his group will collaborate with the Paul Scherrer Institute, the EPFL, and Seoul National University.
Source: unifr.ch

JOURNAL NEWS

Helvetica, Volume 104, Issue 10, October 2021



Reviews

Cyclic Haloiodanes: Syntheses, Applications and Fundamental Studies
Raphaël Robidas, Claude Y. Legault

Essays

Effective Mentoring and the Problem of Assessing Quality in Science
Manfred T. Reetz

Communications

Preparation and Characterization of Pentafluoro- λ^6 -sulfanyldifluoromethane and Pentafluoro- λ^6 -sulfanyl-1,1,2,2-tetrafluoroethane

Steven P. Belina, Si-Yan Qing, Piotr Dudziński, Andrej V. Matsnev, Christian Mück-Lichtenfeld, Günter Haufe, Joseph S. Thrasher

Paramagnetic Oxygen as Contrast Agent for a Potential PDT Treatment MRI Monitoring

Sylviane Chevreux, Mickaël Four, Gilles Lemerrier

Spirocyclic Amide Acetal Synthesis by [CpRu]-Catalyzed Condensations of α -Diazo- β -Ketoesters with γ -Lactams

Romain Pertschi, Elodie Brun, Adiran de Aguirre, Laure Guénee, Amalia I. Poblador-Bahamonde, Jérôme Lacour

Anti-Markovnikov Addition of Anilines to Aliphatic Terminal Alkynes Catalyzed by an 8-Quinolinolato Rhodium Complex

Yoshihiko Morimoto, Takuya Kochi, Fumitoshi Kakiuchi

Full Papers

Hydroamination of Dihapto-Coordinated Benzene and Diene Complexes of Tungsten: Fundamental Studies and the Synthesis of γ -Lycorane

Katy B. Wilson, Hannah S. Nedzbala, Spenser R. Simpson, Megan N. Ericson, Karl S. Westendorff, Mahendra D. Chordia, Diane A. Dickie, W. Dean Harman

Hydroalkylation of Styrenes with Benzylamines by Potassium Hydride

Jia Hao Pang, Bin Wang, Kohei Watanabe, Ryo Takita, Shunsuke Chiba

Highly Stereoselective Aldol Reactions by Memory of Chirality: Synthesis of Quaternary β -Hydroxy α -Amino Acids

Loïc Roupnel, Régis Guillot, Didier Gori, Baby Viswambharan, Cyrille Kouklovsky, Valérie Alezra

Radical Silyl- and Germylzincation of Propargylic Alcohols

Karen de la Vega-Hernández, Kevin Isaac, Fabrice Chemla, Franck Ferreira, Olivier Jackowski, Alejandro Perez-Luna

Computational Study of Benzosultam Formation through Gold(I)-Catalyzed Ammoniation/Nucleophilic Substitution Reaction

Romain Pertschi, Adiran de Aguirre, Patrick Pale, Aurélien Blanc, Amalia I. Poblador Bahamonde

Methoxycyclization of 1,5-Enynes by Coinage Metal Catalysts: Is Gold Always Superior?

Matthew D. Wodrich, Clémence Corminboeuf

Website: onlinelibrary.wiley.com/journal/15222675

INDUSTRIAL NEWS

Source: www.chemanager-online.com

Lonza and Allarity in Dovitinib Alliance

September 28, 2021: Swiss CDMO Lonza and Danish clinical-stage pharma Allarity Therapeutics have agreed to develop and manufacture anti-cancer therapy dovitinib. The companies are aiming to start manufacturing the product in 2022. A small-molecule, pan-tyrosine kinase inhibitor, dovitinib targets metastatic renal cell carcinoma and is Allarity's most advanced clinical asset currently. The company also sees potential in other indications, such as liver cancer, breast cancer and various solid tumors. "Entering this agreement with Lonza is an important step in our long-term preparations to take dovitinib towards commercialization. Allarity now has a robust agreement covering the production and ongoing supply of dovitinib that we will need in the years to come," said the company's CEO, Steve Carchedi. Lonza will perform drug substance manufacturing and particle

100% Chemie

100% RÖMPP
einfach – zuverlässig – wissen

Gleich nachschlagen:
roempp.thieme.de

NEU in 2020 – RÖMPP 5.0:
• Heimzugang von zuhause
• Playlists für wiederkehrende Recherchen
• bibliographischer Download

Thieme

size reduction by micronization at its site in Visp, Switzerland, while manufacturing of the drug product will take place in Tampa, Florida, USA. As Oncology Ventures, Allarity bought dovitinib from Novartis in April 2018. Then in September 2020, Oncology decided to change its name to Allarity, restructuring its board at the same time. Earlier this month, the Danish pharma presented data at the European Society for Medical Oncology conference demonstrating that patients with renal cell carcinoma selected with a dovitinib drug response predictor (DRP) diagnostic tool had a median survival rate of 15 months compared with 11.2 months for those treated with Bayer's Nexavar (sorafenib). During the final quarter of 2021, Allarity plans to file a new drug application for dovitinib with the US Food and Drug Administration. It has previously filed a pre-market approval application for the dovitinib DRP. The DRP is used to select those patients who, by the genetic signature of their cancer, are found to have a high likelihood of responding to the specific drug. Allarity said by screening patients before treatment, the response rate can be increased significantly. Its DRP platform can be used in all cancer types and is patented for more than 70 anti-cancer drugs. For Lonza, the deal with Allarity comes at a time of rapid expansion. Last week, the company announced a further investment in drug product manufacturing facilities in Switzerland. Another aseptic flexible filling line is being added at its site in Stein to support liquid and lyophilized vial filling and processing, cartridges and pre-filled syringes. Completion is expected in 2023, and more than 70 new jobs will be created. The investment also includes an expansion of drug product services for parenteral dosage forms in Basel, Switzerland, with the new facilities due to be operational in 2024. Last month, the CDMO said it would add a new fill-finish line at its site in Guangzhou, China, which will be ready in 2022. Another project in China, announced in June, involves spending 20 million Swiss francs to expand an API development and manufacturing facility in Nansha. In May, Lonza revealed plans to invest roughly 850 million Swiss francs to build two mammalian facilities at Visp and Portsmouth, New Hampshire, USA, with start-up planned for 2024 and 2023, respectively.

Novartis Boosts Ophthalmology with Arctos Medical Buy

September 30, 2021: Swiss drugmaker Novartis has acquired Arctos Medical, a compatriot start-up developing optogenetic therapies. Financial terms of the deal were not disclosed. The acquisition adds Arctos's pre-clinical optogenetics-based AAV gene therapy program and proprietary technology to Novartis's existing portfolio, which is focused on treating neovascular age-related macular degeneration (nAMD), diabetic macular edema and retinal vein occlusion. Arctos has developed technology for potentially treating inherited retinal dystrophies (IRDs) and other diseases that involve photoreceptor loss, such as AMD. Its therapy creates "replacement photoreceptors" with an optogene delivered to and expressed in specific retinal cells using AAV gene therapy technology. The technology has potential to ad-

dress many forms of IRDs, regardless of the causative mutations, making it possible to address a significantly larger population of patients than existing treatments. "Optogenetics is emerging as a promising therapeutic approach that might restore sight to patients who are legally blind," said Jay Bradner, president of the Novartis Institutes for BioMedical Research. "The Arctos technology builds on our conviction that optogenetic gene therapies may meaningfully help patients battling devastating eye diseases." IRDs, which impact more than 2 million people around the world and often result in complete blindness, can be caused by mutations in more than 100 different genes.

Thermo Fisher Expands US and Swiss Biologics Capacities

October 4, 2021: US scientific services supplier Thermo Fisher Scientific is investing \$82.5 million to expand operations and create 169 jobs at its biologic drug substance manufacturing plant in St. Louis County, Missouri. The expanded facility will manufacture biologic drug substance products for treating a variety of chronic health conditions, including cancers and other life-threatening diseases, as well as Covid-19. Two manufacturing suites will be added, along with new machinery and equipment over a two-year period. The project will give Thermo Fisher the additional ability to provide manufacturing support at the 5,000-liter processing scale, as well as continued support for 2,000-liter processing capacity. In separate news, Thermo Fisher has assumed operational responsibility for a new biologics manufacturing site in Lengnau, Switzerland, expanding the US group's global network and adding 200 employees. The move is part of a strategic partnership with biotech CSL announced on May 27, 2020. Operating under a long-term lease agreement with CSL, the Lengnau site has bioproduction capacity of up to 12,500 liters. "Through our partnership with CSL, this site further strengthens our unique customer value proposition to leverage our scale and depth of capabilities for pharma and biotech customers. With the addition of new high-volume stainless-steel capabilities in Lengnau, we are enabling our customers to start their projects with us and stay with us as their manufacturing requirements grow," said Thermo Fisher Scientific executive vice president Michel Lagarde. Following the completion of site construction in 2022, Thermo Fisher will initially support manufacturing of CSL's next-generation recombinant factor IX product Idelvion for patients with hemophilia B. Over time, the company plans to expand the use of the site to include additional biopharma customers. As well as St. Louis County and Lengnau, Thermo Fisher's biologics manufacturing network also includes sites in Princeton, New Jersey, USA; Groningen, the Netherlands; Brisbane, Australia; and Hangzhou, China.

Evonik Seeking to Sell Lülldorf Site

October 7, 2021: Evonik has decided to sell its Lülldorf site, south of Cologne, Germany, in the medium term. The company said detailed plans for the sale will be finalized by next spring. The goal is to sell the entire site to a new owner, though Evonik



jmp
Julius Müller Performance

TIME TO INNOVATE

Learn how successful chemical companies use data analytics to accelerate processes and reduce cost.

www.jmp.com/chem

Copyright © 2020 SAS Institute Inc. Cary, NC, USA. All rights reserved. G135474US.0820

said it will consider selling parts of the businesses to “various interested parties.” Employee representatives have been notified of the plans. The German chemical producer cites the compulsory phase-out of alkoxide production as the principal reason for the decision to sell Lülldorf. The 100-year-old site uses an amalgam electrolysis process to make the chemical that is used in production of biodiesel as well as in chemical recycling of PET. Essen-based Evonik also produces alkoxides in Rosario, Argentina, and at Mobile, Alabama, in the US, using a different process. Potential investors reportedly have expressed interest in the site, where some 600 people are employed, and annual sales of around €280 million are generated, mainly in production of potassium derivatives and cyanuric chlorides. The latter are back-integrated with plants in neighboring Wesseling. The businesses operating at Lülldorf belong to Evonik’s Functional Solutions business line, part of its Performance Materials division. Following the planned divestment of its superabsorbents business, the company said the site sale is “the next logical step” in the alignment of its portfolio to specialty chemicals. Lülldorf has proven to be a good location for basic chemicals for decades, said Evonik CEO Christian Kullmann. However, with the company’s current focus on high-margin specialty chemicals, continuing to develop the site doesn’t make sense, he said, despite it being well positioned logistically in the heart of the chemicals belt along the Rhine River. Medium-sized companies that could exploit advantages in the existing production network as well as possible synergies with new products would be ideal buyers, Evonik believes.

Brenntag to distribute Dynasylan in eastern Europe

In other news, Evonik has extended its agreement with internationally active German distributor Brenntag to distribute its Dynasylan product line to 16 countries in eastern Europe. Since the 1990s, Brenntag has been distributing the chemical company’s silane products in Germany, Austria and Switzerland. The Dynasylan range is used in many industries to achieve higher performance, better effectiveness and more sustainability, Evonik said. Applications include fiberglass, glass wool, foundry and foundry auxiliaries, adhesives and sealants in addition to filler silanization (artificial marble), paints and coatings, polyurethane and rubber.

CureVac Pulls CVnCoV from EMA Approval Process

October 13, 2021: CureVac is withdrawing its first-generation Covid-19 vaccine candidate, CVnCoV, from the current approval process with the European Medicines Agency. In a statement, the German biotech said the EMA had made it clear that there was no chance of the shot being approved before the second quarter of 2022. By this time, it expects candidates from the second-generation vaccine program it is pursuing with UK drugmaker GlaxoSmithKline (GSK) to have progressed to late-stage clinical development. The Tübingen-based company said also that it will terminate its advance purchase agreement with the European Commission for 405 million doses of the vaccine post-approval. It added however, that it is assessing the possibi-

ty of leveraging CVnCoV commitments for its second-generation vaccine candidates and remains in contact with the Commission. In mid-September, the biotech canceled its contracts with Wacker Chemie and Switzerland’s Celonic Group to toll manufacture CVnCoV, while leaving the deals with Rentschler Biopharma and Novartis intact. It said at the time that contracts with Germany’s Bayer and Fareva of France would not be affected by the changes. The company’s gradual decision to withdraw its first candidate followed disappointing results from the 40,000-subject international Phase 2b/3 trial with CVnCoV, completed earlier in the summer. A subsequent assessment confirmed previous findings that the candidate was only about 48% effective in preventing a Covid-19 infection of any severity. Despite burying its first-generation vaccine hopes, CureVac said it plans to continue exploring additional formulations with GSK after the companies saw encouraging initial data from pre-clinical animal tests. These candidates, it said, are based on new mRNA backbones and include potential variants in multivalent vaccine formats as well as combination vaccines for potential protection against multiple infectious diseases in single injection. CureVac said the decision to withdraw from the EMA process reflected the evolving dynamics of the pandemic response toward a greater need for differentiated vaccines. “The global fight against Covid-19 continues, and we remain committed to making a difference with a safe and efficacious vaccine. This goal has not changed, but the requirements to effectively address the virus and emerging variants have changed,” said CEO Franz-Werner Haas.

Mass Spectrometry for Chemists with the expression CMS



Fast reaction
monitoring through
analysis in seconds



Direct mass
analysis from
TLC-plates



With transfer unit
for air-sensitive
samples

Advion

For more information:
central-europe@advion.com
www.expressioncms.com